BLIS M18 TM Gains Australian Regulatory Approval

Blis Technologies Limited: 81 Glasgow Street, South Dunedin 9012, PO Box 5804, Dunedin 9058, New Zealand
T:+64 3 474 0988 E: info@blis.co.nz W: www.blis.co.nz




BLIS M18
TM
Gains Australian Regulatory Approval
Blis Technologies has received notification from the Australian Therapeutic Goods
Administration, that its probiotic strain Streptococcus salivarius BLIS M18 has been
approved as an active ingredient for Listed Complementary Medicines.
CEO Brian Watson said, “This approval represents another important milestone for
the company allowing us to progress plans for the launch of BLIS M18 based
products in the Australian market with our distribution partner iNova
Pharmaceuticals. iNova are in the early stages of launching the BLIS K12
TM
based
product range in Australia which has had a positive response from the Pharmacy
channel. We are excited about the opportunity to build on this positive momentum
with a future BLIS M18 product launch”
For further information please contact:
Brian Watson
CEO Blis Technologies
027 7059133


About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production
controls enables the delivery of probiotic solutions for specific health targets including throat
health, halitosis (bad breath), immune support and teeth and gum health. BLIS products are
sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information
about Blis Technologies Ltd can be found at www.blis.co.nz.
About iNova Pharmaceuticals
iNova Pharmaceuticals (iNova) is a multinational pharmaceutical and consumer health care
company that markets and sells a wide range of market-leading products, primarily in the
areas of weight management, cough & cold, throat, skin care and natural health. iNova
operates in over 20 countries across Asia-Pacific and Africa. The iNova vision is to provide
trusted brands that improve people’s health and well-being every day. iNova is continually
seeking innovative prescription medicines and consumer health care products through
acquisition, licensing and co-marketing partnerships. iNova is ultimately owned by funds
advised and managed by Pacific Equity Partners and The Carlyle Group. More information
about iNova can be found at www.inovapharma.com.